Tampere University of Technology

TUTCRIS Research Portal

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS)

Research output: Contribution to journalReview ArticleScientificpeer-review


Original languageEnglish
Pages (from-to)388-394
Number of pages7
JournalBJU International
Issue number3
Publication statusPublished - Aug 2011
Publication typeA2 Review article in a scientific journal


OBJECTIVE To assess the efficacy and safety of dutasteride compared with finasteride in treating men with symptomatic benign prostatic hyperplasia (BPH) for 12 months. PATIENTS AND METHODS The Enlarged Prostate International Comparator Study was a multicentre, randomized, double-blind, 12-month, parallel-group study. Men aged ≥50 years with a clinical diagnosis of BPH received once-daily treatment with dutasteride 0.5 mg (n= 813) or finasteride 5 mg (n= 817). After a 4-week placebo run-in period, patients were randomized to receive dutasteride or finasteride for 48 weeks, followed by an optional 24-month, open-label phase, during which patients received dutasteride 0.5 mg once daily. The primary endpoint was change in prostate volume, and the secondary endpoints included improvement in American Urological Association Symptom Index (AUA-SI) scores, improvement in maximum urinary flow rate (Q max) and long-term safety in the 24-month open-label phase. RESULTS Both dutasteride and finasteride were effective at reducing prostate volume with no significant difference between the two treatments during the study. Similar reductions in mean AUA-SI scores and Qmax were also observed for men in both treatment groups. A similar percentage of adverse events was experienced by patients of both treatment groups, and no new adverse events were reported in the open-label phase. CONCLUSION Dutasteride and finasteride, when administered for 12 months, were similarly effective in reducing prostate volume and improving Qmax and urinary symptoms associated with BPH in men with an enlarged prostate.

ASJC Scopus subject areas


  • 5α-reductase inhibitors, benign prostatic hyperplasia, dutasteride, finasteride